Acquired Company

Oragenics acquired Odyssey Health’s neurological drug technology pipeline including the concussion asset ONP-002 and Odyssey’s nasal delivery technology on December 28, 2023.

Oragenics, Inc. is a biotechnology firm headquartered in Tampa, Florida, dedicated to the development of innovative therapies and antibiotics aimed at addressing the challenges posed by infectious diseases, particularly those stemming from antibiotic-resistant pathogens. Harnessing its proprietary technologies, the company is focused on advancing a diverse therapeutic pipeline that meets critical healthcare needs. Through strategic collaborations and rigorous research initiatives, Oragenics is positioning itself as a key player in the global fight against infectious diseases, ultimately striving to enhance public health and patient outcomes. Show more

Location: 1990 MAIN STREET, SARASOTA, FL, UNITED STATES, 34236, Sarasota, FL, 34236, USA | Website: https://www.oragenics.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

2.708M

52 Wk Range

$0.63 - $9.60

Previous Close

$0.65

Open

$0.69

Volume

167,309

Day Range

$0.63 - $0.76

Enterprise Value

-8.301M

Cash

11.4M

Avg Qtr Burn

-2.985M

Insider Ownership

2.39%

Institutional Own.

13.17%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ONP-002 Details Traumatic brain injury	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.